Abstract:The pandemic of coronavirus disease 2019 (COVID-19) is changing the world like never before. This crisis is unlikely contained in the absence of effective therapeutics or vaccine. The papain-like protease (PLpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) plays essential roles in virus replication and immune evasion, presenting a charming drug target. Given the PLpro proteases of SARS-CoV-2 and SARS-CoV share significant homology, inhibitor developed for SARS-CoV PLpro is a promising starting point of therapeutic development. In this study, we sought to provide structural frameworks for PLpro inhibitor design. We determined the unliganded structure of SARS-CoV-2 PLpro mutant C111S, which shares many structural features of SARS-CoV PLpro. This crystal form has unique packing, high solvent content and reasonable resolution 2.5 Å, hence provides a good possibility for fragment-based screening using crystallographic approach. We characterized the protease activity of PLpro in cleaving synthetic peptide harboring nsp2/nsp3 juncture. We demonstrate that a potent SARS-CoV PLpro inhibitor GRL0617 is highly effective in inhibiting protease activity of SARS-CoV-2 with the IC50 of 2.2 ± 0.3 μmol/L. We then determined the structure of SARS-CoV-2 PLpro complexed by GRL0617 to 2.6 Å, showing the inhibitor accommodates the S3-S4 pockets of the substrate binding cleft. The binding of GRL0617 induces closure of the BL2 loop and narrows the substrate binding cleft, whereas the binding of a tetrapeptide substrate enlarges the cleft. Hence, our results suggest a mechanism of GRL0617 inhibition, that GRL0617 not only occupies the substrate pockets, but also seals the entrance to the substrate binding cleft hence prevents the binding of the LXGG motif of the substrate.

The Crystal Structures of Severe Acute Respiratory Syndrome Virus Main Protease and Its Complex with an Inhibitor

Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug Design.

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Cryo-electron Microscopy Structures of the SARS-CoV Spike Glycoprotein Reveal a Prerequisite Conformational State for Receptor Binding

Crystallization and Preliminary Crystallographic Analysis of the Heptad-Repeat Complex of Sars Coronavirus Spike Protein

Biosynthesis, Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus 3C-Like Proteinase

Characterization of the Heptad Repeat Regions, HR1 and HR2, and Design of a Fusion Core Structure Model of the Spike Protein from Severe Acute Respiratory Syndrome (SARS) Coronavirus.

Crystal structure of SARS-CoV-2 main protease in complex with a Chinese herb inhibitor shikonin

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Synthetic Peptides Outside the Spike Protein Heptad Repeat Regions As Potent Inhibitors of Sars-Associated Coronavirus

Crystal structures of main protease (M pro ) mutants of SARS-CoV-2 variants bound to PF-07304814

Structural Insights into Sars Coronavirus Proteins

Crystal Structure of SARS-CoV-2 Main Protease (mpro) Mutants in Complex with the Non-Covalent Inhibitor CCF0058981.

Crystal structures of main protease (Mpro) mutants of SARS-CoV-2 variants bound to PF-07304814

Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase.

Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2

[Modeling of the SARS Coronavirus Main Proteinase and Conformational Flexibility of the Active Site].

Insight into the activity of SARS main protease: Molecular dynamics study of dimeric and monomeric form of enzyme.

Structural, Electronic, and Electrostatic Determinants for Inhibitor Binding to Subsites S1 and S2 in SARS-CoV-2 Main Protease

Crystal Structure of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Fusion Core

Crystal structure of SARS-CoV-2 papain-like protease